9M?ٜ[y}SLֳڵ``Yձ2s%~ad9<`U~8 (o;MÜ{EVx ՜tS. Bz;(펠v$bYm.d wKI9Zg)F w-})WEe_d ;:QPTtT@X] U J?H75{ # eWm&"U6h,Ӗi:*b]Cr''DGҗL@Q*Ϸl!Ns!B.[J!ř7)p =dBI/@NxC钔/BpnX@ } $*k}wTj?_x'%z*I3}yD ldc0o >(Z¿_&w[a;?O Z6 '퓇 k=B# J/RU 袶i߲TEKyZ.e Rrg
。Innodata EVP Ashok Mishra sells $67,560 in stockFoxy Brown sparks speculation with cryptic Instagram posts amid Jay-Z allegations
Worcester marks 25th anniversary of fire that killed 6 firefighters
NoneAhead of the Big Ten Title game between Oregon and Penn State, hot dog-eating legend Joey Chestnut set a world record by consuming 21 pounds of shrimp. The famous shrimp cocktail from St. Elmo Steak House in Indianapolis was served at the event. Known for its legendary heat in the signature sauce, it's considered an achievement just to finish a single serving, according to Saturday Down South's Paul Harvey . The competitors and Chestnut took it to a whole other level. Before Saturday's competition, Chestnut's shrimp cocktail record was 18 pounds eaten in 18 minutes. "Last year I was being lazy, I only did 15 pounds, I got beat," Chestnut said on the Bob and Tom Show on Friday. "I'm felling good today, or hopefully, I will be ready tomorrow." The 41-year-old kicked off his notable career in 2007 at Nathan's Famous Fourth of July Hot Dog Eating Contest , where he defeated Takeru Kobayashi to bring the "Mustard Yellow Belt" back to the United States. That victory kicked off an eight-year title streak, during which he went undefeated until 2014, before regaining the title in 2016. He holds the world record for most hot dogs eaten, devouring 76 hot dogs and buns in 10 minutes. The 16-time champion was banned from Nathan's Hot Dog Eating Contest in 2024 for his sponsorship with Impossible Foods. He also holds 55 world records across 55 different foods, including pulled pork sandwiches, Taco Bell tacos, meat pies and asparagus, to name a few.
Scientists have raised concerns about hospitality staff coming into contact with second-hand smoke at work after the Government rowed back on plans to make it illegal to smoke in pub beer gardens. Concerns have also been raised about the “renormalisation” of smoking. Dr Rachel O’Donnell, senior research fellow at the University of Stirling’s Institute for Social Marketing and Health, said restrictions on smoking in outdoor places can “reinforce” a message that smoking “isn’t a socially acceptable thing to do” and could also help smokers to kick the habit. In November, it emerged that the UK Government is to scrap plans to ban smoking in the gardens of pubs and restaurants in England. Health Secretary Wes Streeting said the hospitality industry has “taken a real battering in recent years” and it is not “the right time” to ban smoking outside pubs. But smoking and vaping could be banned in other public places in England – such as in playgrounds or outside of schools – under the Tobacco and Vapes Bill. According to the World Health Organisation, there is no safe level of second-hand smoke exposure. In a briefing for journalists, Dr O’Donnell said decision-making “should be on the basis of all the evidence that’s available”. She added: “Any debate about legislation on smoking in outdoor settings shouldn’t only focus on air quality and second-hand smoke exposure levels, because the impacts of restrictions in outdoor settings are also evident on our social norms.” Smoke-free outdoor environments “reinforce smoke-free as the acceptable norm”, she said. “This, I think, is a critically important point at a time where in the media, over the last year, we’ve seen various reports and questions as to whether we might be on the cusp of renormalisation of smoking for various reasons, and so smoke-free public environments still have a critically important role to play. “If you reduce opportunities to smoke, it can also help individuals who smoke themselves to reduce the amount they smoke or to make a quit attempt.” Dr O’Donnell said visibility of tobacco products and smoking is a “form of marketing for tobacco companies” as she pointed to studies highlighting the increasing number of tobacco depictions on screen. She went on: “The more often young adults observe smoking around them, the more likely they are to believe that smoking is socially acceptable, which feeds back into this idea of renormalisation of smoking. “So, restrictions on smoking in outdoor public places have other positive knock-on effects, potentially for young people as well, just sending out that clear message that this isn’t a socially acceptable thing to do and see, and this could help to discourage smoking initiation among young people at quite a critical time.” On being exposed to second-hand smoke at work, she added: “I think sometimes when we think about exposure to second-hand smoke in outdoor settings, in pubs, in restaurants, we think about that sort of occasional customer exposure, the nuisance element of it when people are out enjoying a meal with friends, but we also need to be reminded that this is a repeated occupational exposure for those who are working in hospitality and serving drinks and food. “Now, as we’ve already seen, concentrations of second-hand smoke in these settings are generally low, and they’re likely to present a low risk to health for most healthy people. “But ... there’s no safe level of exposure to second-hand smoke, and so any individual with pre-existing heart, lung or respiratory conditions may be particularly vulnerable even to low levels of exposure. “We know that second-hand smoke is its known carcinogen, and on that basis those exposed in the hospitality sector have a right to be protected. “On that basis, there’s a need to protect them, as there is anybody in any workplace setting from second-hand smoke exposure in all areas of workplaces and spaces.” Sean Semple, professor of exposure science at the University of Stirling’s Institute for Social Marketing and Health, said: “I think that if I were a policy-maker, which I am not, then I would be looking at those occupational exposures as well. “I have asthma, if I was being occupationally exposed to SHS (second-hand smoke), and knowing that I was one of a very small number of workers now being legally exposed to SHS in the workplace, then I might not be very happy about that.” A Department of Health and Social Care spokesperson said: “As part of our 10 Year Health Plan we are shifting focus from sickness to prevention, including tackling the harms of smoking and passive smoking. “The landmark Tobacco and Vapes Bill is the biggest public health intervention in a generation and will put us on track towards a smoke-free UK.”Micron delivers record fiscal Q1 revenue, driven by strong AI demand Data center revenue grew over 40% sequentially and over 400% year over year BOISE, Idaho, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) today announced results for its first quarter of fiscal 2025, which ended November 28, 2024. Fiscal Q1 2025 highlights Investments in capital expenditures, net (2) were $3.13 billion for the first quarter of 2025, which resulted in adjusted free cash flows (2) of $112 million for the first quarter of 2025. Micron ended the quarter with cash, marketable investments, and restricted cash of $8.75 billion. On December 18, 2024, Micron's Board of Directors declared a quarterly dividend of $0.115 per share, payable in cash on January 15, 2025, to shareholders of record as of the close of business on December 30, 2024. Business Outlook The following table presents Micron's guidance for the second quarter of 2025: Further information regarding Micron's business outlook is included in the prepared remarks and slides, which have been posted at investors.micron.com . Investor Webcast Micron will host a conference call on Wednesday, December 18, 2024 at 2:30 p.m. Mountain Time to discuss its first quarter financial results and provide forward-looking guidance for its second quarter. A live webcast of the call will be available online at investors.micron.com . A webcast replay will be available for one year after the call. For Investor Relations and other company updates, follow us on X @MicronTech. About Micron Technology, Inc. We are an industry leader in innovative memory and storage solutions transforming how the world uses information to enrich life for all . With a relentless focus on our customers, technology leadership, manufacturing, and operational excellence, Micron delivers a rich portfolio of high-performance DRAM, NAND, and NOR memory and storage products through our Micron® and Crucial® brands. Every day, the innovations that our people create fuel the data economy, enabling advances in artificial intelligence (AI) and compute-intensive applications that unleash opportunities - from the data center to the intelligent edge and across the client and mobile user experience. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com . © 2024 Micron Technology, Inc. All rights reserved. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners. Forward-Looking Statements This press release contains forward-looking statements regarding our industry, our strategic focus, demand for our products, and our financial and operating results, including our guidance for the second quarter of 2025. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. Please refer to the documents we file with the Securities and Exchange Commission, including our most recent Form 10-K and our upcoming Form 10-Q. These documents contain and identify important factors that could cause our actual results to differ materially from those contained in these forward-looking statements. These certain factors can be found at investors.micron.com/risk-factor . Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We are under no duty to update any of the forward-looking statements to conform these statements to actual results. CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share amounts) (Unaudited) 2024 2024 2023 CONSOLIDATED BALANCE SHEETS (In millions) (Unaudited) 2024 2024Energous Co. ( NASDAQ:WATT – Get Free Report ) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 955,200 shares, an increase of 24.3% from the November 30th total of 768,700 shares. Currently, 9.7% of the company’s stock are short sold. Based on an average trading volume of 227,800 shares, the days-to-cover ratio is presently 4.2 days. Energous Price Performance NASDAQ WATT opened at $0.41 on Friday. Energous has a 52 week low of $0.28 and a 52 week high of $2.75. The firm has a 50 day moving average of $0.47 and a two-hundred day moving average of $0.71. The stock has a market capitalization of $4.10 million, a PE ratio of -0.13 and a beta of 2.60. Energous ( NASDAQ:WATT – Get Free Report ) last issued its earnings results on Tuesday, November 12th. The industrial products company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.24. The firm had revenue of $0.23 million during the quarter. Energous had a negative net margin of 4,368.98% and a negative return on equity of 317.56%. Institutional Investors Weigh In On Energous About Energous ( Get Free Report ) Energous Corporation provides wireless charging system solutions in the United States. The company develops WattUp wireless power networks technology that consists of semiconductor chipsets; software controls; hardware designs; and antennas that enables radio frequency-based charging for Internet of Things devices. Recommended Stories Receive News & Ratings for Energous Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Energous and related companies with MarketBeat.com's FREE daily email newsletter .
Host Hotels & Resorts Inc. stock underperforms Tuesday when compared to competitors despite daily gainsSEOUL, South Korea (AP) — South Korea's embattled President Yoon Suk Yeol avoided an opposition-led attempt to impeach him over his short-lived imposition of martial law , as most ruling party lawmakers boycotted a parliamentary vote Saturday to deny a two-thirds majority needed to suspend his presidential powers. The scrapping of the motion is expected to intensify protests calling for Yoon’s ouster and deepen political chaos in South Korea, with a survey suggesting a majority of South Koreans support the president’s impeachment. Yoon’s martial law declaration drew criticism from his own ruling conservative People Power Party, but the party is also determined to oppose Yoon’s impeachment apparently because it fears losing the presidency to liberals. After the motion fell through, members of the main liberal opposition Democratic Party rallied inside the National Assembly, chanting slogans calling for Yoon's impeachment or resignation. The party's floor leader, Park Chan-dae, said it will soon prepare for a new impeachment motion. Opposition parties could submit a new impeachment motion after a new parliamentary session opens next Wednesday. “We'll surely impeach Yoon Suk Yeol, who is the greatest risk to Republic of Korea,” party leader Lee Jae-myung said. “We'll surely bring back this country to normal before Christmas Day or year's end.” Many experts worry Yoon won’t be able to serve out his remaining 2 1⁄2 years in office. They say some PPP lawmakers could eventually join opposition parties’ efforts to impeach Yoon if public demands for it grow further. The ruling party risks "further public outrage and national confusion if they don’t find a formula fast for Yoon’s departure,” said Duyeon Kim, a senior analyst at the Center for a New American Security in Washington. PPP chair Han Dong-hun said his party will seek Yoon’s “orderly” early exit but didn’t say when he can resign. On Saturday, tens of thousands of people packed several blocks of roads leading to the National Assembly, waving banners, shouting slogans and dancing. Protesters also gathered in front of PPP’s headquarters near the Assembly, shouting for its lawmakers to vote to impeach Yoon. A smaller crowd of Yoon’s supporters, which still seemed to be in the thousands, rallied elsewhere in Seoul, calling the impeachment attempt unconstitutional. Impeaching Yoon required support from 200 of the National Assembly's 300 members. The Democratic Party and five other small opposition parties, which filed the motion, have 192 seats combined. But only three lawmakers from PPP participated in the vote. The motion was scrapped without ballot counting because the number of votes didn’t reach 200. National Assembly Speaker Woo Won Shik called the result “very regrettable” and an embarrassing moment for the country’s democracy. If Yoon is impeached, his powers will be suspended until the Constitutional Court decides whether to remove him from office. If he is removed, an election to replace him must take place within 60 days. Earlier Saturday, Yoon issued an apology over the martial law decree, saying he won’t shirk legal or political responsibility for the declaration and promising not to make another attempt to impose it. He said would leave it to his party to chart a course through the country’s political turmoil, “including matters related to my term in office.” “The declaration of this martial law was made out of my desperation. But in the course of its implementation, it caused anxiety and inconveniences to the public. I feel very sorry over that and truly apologize to the people who must have been shocked a lot,” Yoon said. Since taking office in 2022, Yoon has struggled to push his agenda through an opposition-controlled parliament and grappled with low approval ratings amid scandals involving himself and his wife. In his martial law announcement on Tuesday night, Yoon called parliament a “den of criminals” bogging down state affairs and vowed to eliminate “shameless North Korea followers and anti-state forces.” The declaration of martial law was the first of its kind in more than 40 years in South Korea. The turmoil has paralyzed South Korean politics and sparked alarm among key diplomatic partners like the U.S. and Japan. “Yoon’s credibility overseas has been undermined by declaring martial law, so he won’t be able to exercise leadership in his foreign policies especially when his days are numbered,” Kim, the analyst, said. “Its government bureaucracy will need to continue business as usual for existing alliance and foreign policy initiatives as best it can because there is a lot of important work to do globally.” Tuesday night saw special forces troops encircling the parliament building and army helicopters hovering over it, but the military withdrew after the National Assembly unanimously voted to overturn the decree, forcing Yoon to lift it before daybreak Wednesday. Eighteen lawmakers from the ruling party voted to reject Yoon’s martial law decree along with opposition lawmakers. PPP later decided to oppose Yoon's impeachment motion. Yoon’s speech fueled speculation that he and his party may push for a constitutional amendment to shorten his term, instead of accepting impeachment, as a way to ease public anger over the marital law and facilitate Yoon’s early exit from office. Lee told reporters that Yoon’s speech was “greatly disappointing” and that the only way forward is his immediate resignation or impeachment. His party called Yoon’s martial law “unconstitutional, illegal rebellion or coup.” Lawmakers on Saturday first voted on a bill appointing a special prosecutor to investigate stock price manipulation allegations surrounding Yoon’s wife. On Friday, Han, who criticized Yoon’s martial law declaration, said he had received intelligence that during the brief period of martial law Yoon ordered the country’s defense counterintelligence commander to arrest unspecified key politicians based on accusations of “anti-state activities.” Hong Jang-won, first deputy director of South Korea’s spy agency, told lawmakers Friday that Yoon had ordered him to help the defense counterintelligence unit to detain key politicians including Han, Lee and Woo. The Defense Ministry said Friday it suspended three military commanders including the head of the defense counterintelligence unit over their involvement in enforcing martial law. Vice Defense Minister Kim Seon Ho has told parliament that Defense Minister Kim Yong Hyun ordered the deployment of troops to the National Assembly. Opposition parties accused Kim of recommending to Yoon to enforce martial law. Kim Yong Hyun resigned Thursday, and prosecutors imposed an overseas travel ban on him.
'Open your doors': Notre Dame re-opens after five-year refitSyrian insurgents reach the capital's suburbs. Worried residents flee and stock up on supplies BEIRUT (AP) — Insurgents’ stunning march across Syria is gaining speed with news that they have reached the suburbs of the capital of Damascus. The government on Saturday was forced to deny rumors that President Bashar Assad had fled the country. The rebels’ moves around Damascus were reported by an opposition war monitor and a rebel commander. They came after the Syrian army withdrew from much of southern part of the country, leaving more areas, including two provincial capitals, under the control of opposition fighters. The advances in the past week were among the largest in recent years by opposition factions. The factions are by a group that has its origins in al-Qaida and is considered a terrorist organization by the U.S. and the United Nations. An archbishop's knock formally restores Notre Dame to life as winds howl and heads of state look on PARIS (AP) — France’s iconic Notre Dame Cathedral has formally reopened its doors for the first time since a devastating fire nearly destroyed the 861-year-old landmark in 2019. The five-year restoration is widely seen as a boost for French President Emmanuel Macron, who championed the ambitious timeline, and brings a welcome respite from his domestic political woes. World leaders, dignitaries, and worshippers gathered on Saturday evening for the celebrations under the cathedral's soaring arches. The celebration was attended by 1,500 dignitaries, including President-elect Donald Trump, Britain’s Prince William, and Ukrainian President Volodymyr Zelenskyy. For Catholics, Notre Dame’s rector said the cathedral “carries the enveloping presence of the Virgin Mary, a maternal and embracing presence.′′ Trump is welcomed by Macron to Paris with presidential pomp and joined by Zelenskyy for their talks PARIS (AP) — French President Emmanuel Macron has welcomed Donald Trump to Paris with a full a dose of presidential pomp. And they held a hastically-arranged meeting with Ukraine’s Volodymyr Zelenskyy on a day that's mixing pageantry with attention to pressing global problems. The president-elect's visit to France is part of a global a celebration of the reopening of Notre Dame Cathedral five years after a devastating fire. Macron and other European leaders are trying to win Trump’s favor and persuade him to maintain support for Ukraine in its defense against Russia’s invasion. Trump isn't back in office but he's already pushing his agenda and negotiating with world leaders NEW YORK (AP) — Donald Trump is making threats, traveling abroad, and negotiating with world leaders. He has more than a month-and-a-half to go before he’s sworn in for a second term. But the president-elect is already moving aggressively to not only fill his Cabinet and outline policy goals, but also to try to achieve his priorities. In recent days, Trump has threatened to impose a 25% tariff on goods from Canada and Mexico, two of the country’s largest trading partners. That led to emergency calls and a visit. And he's warned of “ALL HELL TO PAY” if Hamas doesn't release the hostages still being held captive in Gaza. South Korea's president avoids an impeachment attempt over short-lived martial law SEOUL, South Korea (AP) — South Korea’s embattled President Yoon Suk Yeol has avoided an opposition-led attempt to impeach him over his short-lived imposition of martial law. Most of Yoon's ruling party lawmakers boycotted a parliamentary vote Saturday to deny a two-thirds majority needed to suspend his presidential powers. The scrapping of the motion is expected to intensify protests calling for Yoon’s ouster and deepen political chaos in South Korea. A survey suggests a majority of South Koreans support the president’s impeachment. Yoon’s martial law declaration drew criticism from his own ruling conservative People Power Party. But the party also apparently fears losing the presidency to liberals. Days after gunman killed UnitedHealthcare's CEO, police push to ID him and FBI offers reward NEW YORK (AP) — Nearly four days after the shooting of UnitedHealthcare CEO Brian Thompson, police still do not know the gunman’s name or whereabouts or have a motive for the killing. But they have made some progress in their investigation into Wednesday's killing of the leader of the largest U.S. health insurer, including that the gunman likely left New York City on a bus soon after fleeing the scene. The also found that the gunman left something behind: a backpack that was discovered in Central Park. Police are working with the FBI, which on Friday night announced a $50,000 reward for information leading to an arrest and conviction. UnitedHealthcare CEO's shooting opens a door for many to vent frustrations over insurance The fatal shooting of UnitedHealthcare's CEO has opened the door for many people to vent their frustrations and anger over the insurance industry. The feelings of exasperation, anger, resentment, and helplessness toward insurers aren’t new. But the shooting and the headlines around it have unleashed a new wave of patients sharing such sentiments and personal stories of interactions with insurance companies. Conversations at dinner tables, office water coolers, social gatherings and on social media have pivoted to the topic. Many say they hope the new amplified voices can bring about change for companies often accused of valuing profits over people. 100-year-old Pearl Harbor survivor recalls confusion and chaos during Japanese bombing 83 years ago PEARL HARBOR, Hawaii (AP) — The bombing of Pearl Harbor 83 years ago launched the United States into World War II. Two survivors are planning to return to the Hawaii military base on Saturday for a remembrance ceremony on the attack's anniversary. They are each over 100 years old. They will join active-duty troops, veterans and members of the public for a remembrance ceremony hosted by the Navy and the National Park Service. A third survivor was planning to join them but had to cancel due to health issues. The bombing killed more than 2,300 U.S. servicemen. An explosion destroys an apartment block in a Dutch city, killing at least 3 and injuring others THE HAGUE, Netherlands (AP) — An explosion and fire has rocked a neighborhood in the Dutch city of The Hague, killing three people and injuring other people and destroying several apartments. The cause of the disaster is unclear. Emergency authorities said four people were rescued from the rubble and taken to the hospital. The mayor said rescuers were no longer looking for survivors but for eventual bodies, but could not specify how many people might still be unaccounted for. Residents of the northeastern neighborhood of Mariahoeve in The Hague heard a huge bang and screams before dawn. Dutch authorities have deployed a specialized urban search and rescue team to find victims. How 'Mufasa' rose with Aaron Pierre and Blue Ivy's voices along with new Lin-Manuel Miranda music SAN DIEGO (AP) — When Aaron Pierre was cast as Mufasa, the weight of following in the late James Earl Jones’ legendary footsteps was enough to rattle any actor. But instead of letting the pressure roar too loudly, he harnessed his nerves to breathe fresh life into his young lion character. Pierre found parallels between himself and his character while filming his leading role in “Mufasa: The Lion King,” which opens in theaters Dec. 20. He took the reigns as the new voice of Mufasa after Jones played the iconic King Mufasa in both the 1994 and 2019 versions of Disney’s “The Lion King.” The prequel offers a fresh exploration into Mufasa’s origin story.ARLINGTON, Va. (AP) — Alex Ovechkin has not missed many games during his two decades in the NHL with the Washington Capitals, and that remarkable durability is one reason why he is fast-approaching Wayne Gretzky's career goals record. The Capitals had lost 33 of their 59 games without Ovechkin in the lineup during his first 19 seasons, including 23 of 36 over the past decade. In stark contrast to that, they've won six of nine since the 39-year-old captain was sidelined by a broken left fibula — a testament to a roster built not only to help him break the record but prepare the organization for the post-Ovechkin era. “Ovi, he’s a legend, he’s special, he’s always going to probably lead the team in goals and we’re a better team with him, but we’re also a team where I think we’re not necessarily maybe relying on one or two players to win games,” said center Lars Eller, who rejoined the team in a trade from Pittsburgh a month ago. “We have four pretty strong lines, three D pairs and two good goalies. We don’t depend on one or two individuals, and I think that’s the strength of the team.” Depth fortified by the additions of centers Dylan Strome , Pierre-Luc Dubois and Eller, wingers Andrew Mangiapane , Brandon Duhaime and Taylor Raddysh, defensemen Jakob Chychrun, Matt Roy and Rasmus Sandin and goaltenders Charlie Lindgren and Logan Thompson over the past few years has been the key to remaining a playoff contender. Longtime general manager Brian MacLellan, who after the most recent makeover this past summer handed day-to-day duties to Chris Patrick and moved upstairs as president of hockey operations, excelled in keeping Washington's winning window open with Ovechkin in the second-to-last year of his contract. Veteran defenseman John Carlson said the infusion of talent “really lit a fire under everybody.” The Capitals led the Eastern Conference when Ovechkin got injured Nov. 18, and they remain atop the East more than three weeks into his absence. Fourteen players have scored a goal during this stretch, including six wins and an overtime defeat since losing the first two without him. “We’re a deep group,” said right winger Tom Wilson, the team's leading scorer during this stretch with nine points on five goals and four assists who expects to continue playing with a shield protecting his face after breaking a small bone in the sinus cavity area on the left side. "Everybody’s kind of stepping up on any given night. It’s a real group effort, and I think guys are really playing for each other.” Carlson, who along with Ovechkin, Wilson and now Eller upon return are the only players left from Washington's 2018 Stanley Cup championship team, also sees it as a case of younger teammates taking advantage of this chance. “There’s the colossal emptiness of it, but there’s also a lot of opportunity for guys who would never otherwise be there when he’s on this team,” Carlson said. “When someone goes down, it’s obviously always kind of a rallying thing where guys need to step up, guys need to fill in and play bigger roles and play more minutes. But I think the way that our team’s built is depth, and that’s been our strength this year is kind of contributions from everybody.” Ovechkin led all players with 15 goals when he went down, and the Capitals were the high-scoring team in the league at 4.33 goals a game. They still are, down just a tick to an average of 4.04, and their 16 goals from defensemen are a big reason for that after ranking second-last in blue line production last season. “We’re playing to our structure and doing what we want to do out there,” said Chychrun, who has eight points in nine games as part of an impressive start to his contract year. “We’ve got a D corps where everybody’s a really good player on that back end and can play in all situations and two-way guys and guys who have contributed offensively throughout their career.” Another major defense is second-year coach Spencer Carbery , who acknowledged the structure and playing standard as a good place to start but pointed the credit to veteran leaders like Carlson, Strome, Wilson and Nic Dowd for shepherding the Capitals through Ovechkin-less hockey. “They don’t go around the room and go, ‘Hey, we’ve got to do more, guys,’” Carbery said. “They don’t announce it, but what they do is they think about it and go: ‘OK, we’re missing him. I’ve got to step my game up and I need to bring more.’ And that’s not just on the ice, on the power play, on 5 on 6 when we’re defending a lead. It’s not just the Xs and Os. It’s in the locker room. It’s energy in practice. It’s all the things that he brings every day when he’s in the lineup and when he’s practicing.” Ovechkin skated before practice Wednesday and got an assist from longtime running mate Nicklas Backstrom, who stepped away 13 months ago because of a lingering hip injury. Carlson quipped, “I think Ovi wanted someone with a little more skill passing him the rock out there.” The day is coming soon when Ovechkin returns to team drills and then game action. The Capitals are doing more than stay afloat without him, but they'll welcome him back with open arms the moment he's ready. As Eller said, “Obviously I think we’re even better when he’s in the lineup.” ___ AP NHL: https://apnews.com/hub/nhl Stephen Whyno, The Associated Press
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenJ.M. Smucker Co. stock falls Tuesday, underperforms marketInnodata EVP Ashok Mishra sells $67,560 in stock
